Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis

I. Hsin Huang, Po Chien Wu, Ting Hua Yang, Hua Li, Yu Ting Huang, Ying Chih Cheng, Po Hsiu Kuo, Ya Han Lee, Yu Chen Huang, Yu Kang Tu

研究成果: 雜誌貢獻文章同行評審

摘要

Background: Various systemic immunomodulating therapies have been investigated to treat nail psoriasis, but the efficacy remains unclear. Objective: To perform a systematic review and network meta-analysis to evaluate the efficacy of small molecule inhibitors and biologics in treating nail psoriasis. Methods: Eligible studies in online databases were identified until March 10, 2020. To assess the efficacy of small molecule inhibitors and biologics, network meta-analyses with surface under the cumulative ranking curve of improvement in nail score at 10 to 16 and at 24 to 26 weeks, as well as 100% improvement of Nail Psoriasis Severity Index (NAPSI), were performed. Results: Thirty-nine studies with a total of 13 treatment arms involving 15,673 patients with nail psoriasis were included. An network meta-analysis showed that tofacitinib (weighted mean difference, 56.67; 95% confidence interval [CI], 35.87-77.48) and ixekizumab (weighted mean difference, 59.40; 95% CI, 45.87-72.93) presented the most improvement of nail score at 10 to 16 weeks and 24 to 26 weeks, respectively. For 100% improvement of the Nail Psoriasis Severity Index, ixekizumab showed the best efficacy among all treatments (odds ratio, 2.98; 95% CI, 1.74-5.10). Limitations: Insufficiency of eligible data and no long-term follow-up data. Conclusion: Tofacitinib and ixekizumab presented the best efficacy for treating nail psoriasis in 10 to 16 weeks and 24 to 26 weeks, respectively.
原文英語
頁(從 - 到)135-143
頁數9
期刊Journal of the American Academy of Dermatology
85
發行號1
DOIs
出版狀態接受/付印 - 2021

ASJC Scopus subject areas

  • 皮膚科

指紋

深入研究「Small molecule inhibitors and biologics in treating nail psoriasis: A systematic review and network meta-analysis」主題。共同形成了獨特的指紋。

引用此